u/Pete26l96

Reddit r/ValueInvesting
· tracked since Feb 2026
Calls
4
Win Rate
75.0%
return
+13.4%
Calls 4 2 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Best Calls
AMZN Long +23.3%
GOOGL Long +19.1%
NVO Long +18.0%
Worst Calls
META Long -6.8%
Most Mentioned
META ×1
AMZN ×1
NVO ×1
Recent Calls
META Long 5 months ago
AMZN Long 5 months ago
GOOGL Long 5 months ago
Win Rate 75% Long 4 Short 0
Win Rate
7d 75%
30d 75%
90d 75%
Average Return +13.4% Long Return +13.4% Short Return -
Average Return
7d +3.8%
30d +12.8%
90d +9.0%
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Mar 26
$210.50
+23.3%
AWS leads Azure in infrastructure and output. Amazon offers a more compelling infrastructure play with a wider moat than Microsoft. Amazon is a better buy than MSFT despite lagging stock performance over the last 5 years. Slowdown in cloud spending or retail margin compression.
AWS leads Azure in infrastructure and output. Amazon offers a more compelling infrastructure play with a wider moat than Microsoft. Amazon is a better buy than MSFT despite lagging stock performance over the last 5 years. Slowdown in cloud spending or retail margin compression.
Hyperscalers
Long
Mar 26
$289.83
+19.1%
Google is at the forefront of AI and innovation, and Gsuite is replacing Office in government sectors. For a slightly higher valuation than MSFT, Google offers superior technological leadership and market share capture. Buy Google over MSFT for better long-term value and AI exposure. Regulatory/antitrust risks or failure to monetize AI effectively.
Google is at the forefront of AI and innovation, and Gsuite is replacing Office in government sectors. For a slightly higher valuation than MSFT, Google offers superior technological leadership and market share capture. Buy Google over MSFT for better long-term value and AI exposure. Regulatory/antitrust risks or failure to monetize AI effectively.
Hyperscalers
Long
Mar 26
$593.00
-6.8%
Meta has a very tight grip on the social media landscape. Meta's monopoly in social media is stronger than Microsoft's current grip on the software/hardware space. Meta makes more sense as a long-term investment than MSFT. Ad-spending downturns or regulatory actions against social media.
Meta has a very tight grip on the social media landscape. Meta's monopoly in social media is stronger than Microsoft's current grip on the software/hardware space. Meta makes more sense as a long-term investment than MSFT. Ad-spending downturns or regulatory actions against social media.
Hyperscalers
Long
Feb 23
$39.63
+18.0%
NVO's stock price has dropped significantly due to negative news about a single drug trial, falling from a high of ~1000 DKK to ~250 DKK. The speaker argues that the market is irrationally focused on the speculative weight-loss drug pipeline while ignoring the stable, profitable core business in insulin. They assert that the company's fundamentals remain intact and the sell-off is driven by "stupid people" and sentiment, not a change in intrinsic value. This has pushed the stock from an overvalued "To the moon!" price into undervalued territory. This is a fundamental value investing opportunity. The thesis is to buy a high-quality company with a stable core business after its price has been punished by market irrationality and short-term sentiment, creating a significant margin of safety. The speaker's assessment that the weight-loss drug market is just "hype" could be wrong; this market could become the primary value driver for NVO and its competitors. A permanent loss of competitive ground to Eli Lilly in this segment could severely impair future growth and justify a lower valuation, making the current price a value trap rather than a bargain. TICKER - DIRECTION
NVO's stock price has dropped significantly due to negative news about a single drug trial, falling from a high of ~1000 DKK to ~250 DKK. The speaker argues that the market is irrationally focused on the speculative weight-loss drug pipeline while ignoring the stable, profitable core business in insulin. They assert that the company's fundamentals remain intact and the sell-off is driven by "stupid people" and sentiment, not a change in intrinsic value. This has pushed the stock from an overvalued "To the moon!" price into undervalued territory. This is a fundamental value investing opportunity. The thesis is to buy a high-quality company with a stable core business after its price has been punished by market irrationality and short-term sentiment, creating a significant margin of safety. The speaker's assessment that the weight-loss drug market is just "hype" could be wrong; this market could become the primary value driver for NVO and its competitors. A permanent loss of competitive ground to Eli Lilly in this segment could severely impair future growth and justify a lower valuation, making the current price a value trap rather than a bargain. TICKER - DIRECTION
GLP-1 / Obesity
Showing 4 of 4 calls · sorted by mentions

u/Pete26l96 has 4 trade ideas tracked on Buzzberg across 4 tickers since February 2026. Most covered: META, AMZN, NVO.